TACR1 and cancer: Therefore, although we found a relatively high rate of triple antiemetic regimen use in Hokushin region compared with other studies [8–10], further studies are needed regarding the effects of adding neurokinin-1 receptor antagonist to each carboplatin-based regime and different types of cancer.